Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending February 2012. The report serves as a notification of transactions involving directors, persons discharging managerial responsibility (PDMR), or connected persons, specifically regarding the vesting of conditional share awards under the GlaxoSmithKline Share Value Plan (SVP).
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on equity compensation events. The only financial data point provided is the closing middle market price of an Ordinary share on February 17, 2012, which was £14.14.
Material Changes
The material event reported is the conclusion of the three-year vesting period for SVP awards made in 2009. The vesting period commenced on February 17, 2009, and ended on February 16, 2012, with the awards vesting on February 17, 2012.
Guidance, Outlook, and Risks
The filing contains no management commentary, guidance, outlook, or discussion of risks and contingencies. It is a compliance notification under Disclosure and Transparency Rule 3.1.4R(1)(c).
Important Facts for Investors
- Transaction Type: Vesting of conditional share awards (Ordinary Shares and ADSs) made in 2009.
- Beneficiaries: Connected persons of Mr. P. Thomson and Dr. M. Slaoui (Executive Director).
- Volume Vested: 588 ADSs vested for Mrs. K. Thomson; 640 Ordinary shares vested for Mrs. K. Slaoui.
- Share Price: The closing middle market price on the vesting date (Feb 17, 2012) was £14.14.
- Notification Date: The company and individuals were advised of these transactions on February 20, 2012.